Scientists have discovered a potential reason why melanoma doesn’t always respond to certain drugs.
For some advanced melanoma patients, immune checkpoint inhibitors — a kind of immunotherapy that pushes the immune system to attack tumors — can lead to long-term remission. But for many patients, the drugs don’t work. Now, scientists at Swiss Federal Institute of Technology in Lausanne studying a mouse model of melanoma have discovered that “bad immune cells” might be limiting how well the drugs work. Their findings were published this week in Science Translational Medicine.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
